Bafna Pharmaceuticals has rallied over 8% to Rs 32.75 on BSE on reports that the promoters of the company intends to divest their stake from the company.
“US-based generic drug maker Mylan and two Indian pharma companies are in the race to acquire Chennai-based Bafna Pharmaceuticals,” Economic Times report suggests.
Bafna Pharmaceuticals makes indictable, generic drugs and haemoglobin drug 'Raricap'.
Meanwhile, the company on Monday said, it has launched pain management and anti-infective products in the domestic market as it looks to expand presence in these segments.
"The company is expanding its base into pain management and anti-infectives by launching Afenac-P tablets, Afnec Th tablets, Nocaf syrup, Izabof suspension and Izabof 250 and 500 mg tablets," Bafna Pharmaceuticals said in a filing to BSE.
The stock opened at Rs 35.95 and has seen over multiple-fold jump in trading volumes. A combined 551,161 shares have already changed hands on the counter till 0935 hours against an average sub 100,000 shares that were traded daily in past two weeks on BSE and NSE.
“US-based generic drug maker Mylan and two Indian pharma companies are in the race to acquire Chennai-based Bafna Pharmaceuticals,” Economic Times report suggests.
Bafna Pharmaceuticals makes indictable, generic drugs and haemoglobin drug 'Raricap'.
Meanwhile, the company on Monday said, it has launched pain management and anti-infective products in the domestic market as it looks to expand presence in these segments.
"The company is expanding its base into pain management and anti-infectives by launching Afenac-P tablets, Afnec Th tablets, Nocaf syrup, Izabof suspension and Izabof 250 and 500 mg tablets," Bafna Pharmaceuticals said in a filing to BSE.
The stock opened at Rs 35.95 and has seen over multiple-fold jump in trading volumes. A combined 551,161 shares have already changed hands on the counter till 0935 hours against an average sub 100,000 shares that were traded daily in past two weeks on BSE and NSE.